APP has received approval from the FDA to market preservative-free methotrexate injection. Currently, the company is manufacturing methotrexate injection with preservative.

Due to the nationwide shortage of preservative-free methotrexate, APP worked collaboratively with the FDA to expedite approval of this critically needed oncology drug. Once APP received notification of the approval, the company immediately began the process of quickly scheduling production so that APP can ship to customers within the next four to six weeks.

Methotrexate is an injectable drug used to treat a variety of cancerous and rheumatologic conditions, including acute lymphoblastic leukemia (ALL).

For more information, visit www.APPpharma.com.